local regional treatment: examining advances in management of breast cancer, dr. marilyn leitch -...
DESCRIPTION
TRANSCRIPT
![Page 1: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/1.jpg)
“Examining Advances in
Management of Breast Cancer
During the Last 30 Years” LOCAL REGIONAL TREATMENT
7th Annual Breast Health Summit Houston, TX
10/21/2011
A. Marilyn Leitch, MD
Professor of Surgery
UT Southwestern
![Page 2: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/2.jpg)
OUTLINE
Trends in breast cancer surgery
Tension between BCS and total mastectomy
Evolution to breast conserving surgery
Increasing rate of bilateral mastectomies
Adoption of Sentinel node biopsy of nodal
staging
Abandonment of ALND for positive sentinel
node
![Page 3: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/3.jpg)
Death rates decreased 31% between 1989 and 2007
![Page 4: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/4.jpg)
5 YEAR RELATIVE SURVIVAL RATES
BREAST CANCER: 1996 to 2005 SEER Data (CA Cancer J Clin 2010)
0
20
40
60
80
100
LOCAL REGIONAL DISTANT
99
85
25
93
72
17
98
84
23
Per
cen
tag
e %
WHITE AFRICAN AMERICAN ALL RACES
![Page 5: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/5.jpg)
Trends in Breast
Cancer Surgery
![Page 6: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/6.jpg)
Trends in Breast Cancer Surgery
BREAST CONSERVATION THERAPY:
LONG-TERM VALIDATION OF SAFETY
![Page 7: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/7.jpg)
SURVIVAL IN RANDOMIZED TRIALS OF
BREAST CONSERVATION VS. MASTECTOMY
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
Gustave-
Roussy
Milan NSABP NCI EORTC Danish
MAST
BCT
![Page 8: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/8.jpg)
20 YEAR FOLLOW-UP OF BREAST
CONSERVATION RANDOMIZED TRIALS:
OVERALL SURVIVAL
NEJM 2002; 347: 1227-32 & 1233-41 CANCER 2003;98 697-702
![Page 9: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/9.jpg)
20 YEAR FOLLOW-UP OF RANDOMIZED
BREAST CONSERVATION TRIALS:
LOCAL RECURRENCE
NEJM 2002; 347: 1227-32 & 1233-41 CANCER 2003;98 697-702
![Page 10: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/10.jpg)
PATTERN OF LOCAL
RECURRENCE OVER TIME: B-06
TOTAL
LR < 5 YRS 5-10 YRS >10 YRS
78
EVENTS
(14.3%) 40% 29% 31%
![Page 11: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/11.jpg)
LOCAL RECURRENCE IN
RECENT BCT TRIALS
NSABP trials since B-06 show lower
rates of LR
6% LR at 10 years in node negative
patients
Attributed to use of adjuvant
systemic therapy
NEJM 2002;347:1233-41
![Page 12: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/12.jpg)
NIH CONSENSUS CONFERENCE
ON EARLY STAGE BREAST
CANCER: 1990
Outcomes of breast conserving surgery similar to mastectomy in randomized trials
Breast conservation therapy is the preferred treatment for most stage I and II breast cancers
![Page 13: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/13.jpg)
INCREASING UTILIZATION OF
BREAST CONSERVATION OVER TIME
0%
10%
20%
30%
40%
50%
60%
70%
1985-89 1995 2000 2007
35%
58%
68% 69%
19%
36%
46% 49%
Stage I
Stage II
Cancer 1999; 86: 628-37 / Cancer 1998;83:1262-73 / Commission on Cancer
Benchmark Reports 9/2003, 9/2010
![Page 14: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/14.jpg)
WHY WOMEN DECLINE
BREAST CONSERVATION
Fear of radiation
Disbelief in radiation efficacy
Inconvenience of prolonged and daily radiation treatments
Lack of radiation treatment facility nearby
Disbelief in equivalency to mastectomy for survival
Strong family history breast cancer
![Page 15: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/15.jpg)
TREND TOWARD MORE AGGRESSIVE
SURGICAL TREATMENT
SEER 1998-2003
• 152,755 patients with stage I-III
breast cancer
3.3% (4969) had contralateral
Prophylactic Mastectomy (PM)
contralateral PM increased from
1.8% to 4.5%
![Page 16: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/16.jpg)
Contralateral Prophylactic Mastectomy (CPM):
Increased Use in U.S.
CPM increased from 4% to 11 % of all
patients having mastectomy
150% increase in opposite breast
mastectomy over 1998-2003 when
treated for Invasive breast cancer in
one breast
![Page 17: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/17.jpg)
More likely to have contralateral
mastectomy if:
Young
White race
More favorable tumors
Women with previous history
of other cancer
Infiltrating lobular cancer
![Page 18: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/18.jpg)
Bilateral Mastectomy Rate INCREASED
FROM 0% TO 10% from 1997-2007
0%
2%
4%
6%
8%
10%
12%
1996 1998 2000 2002 2004 2006 2008
PE
RC
EN
TA
GE
YEAR
UT SOUTHWESTERN EXPERIENCE
![Page 19: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/19.jpg)
ASSISTING WOMEN IN DECISION MAKING
FOR MASTECTOMY OR NOT?
Inform in unbiased way about options- data driven
Discuss alternatives that make lumpectomy without opposite mastectomy less worrisome Adjuvant therapy taken after surgery
Enhanced surveillance with MRI
Lifestyle risk reduction strategies
ONCOPLASTIC ALTERNATIVES for making saved breast more attractive and matching opposite breast Insurance covers these procedures
![Page 20: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/20.jpg)
AXILLARY STAGING:
SENTINEL NODE BIOPSY
MINIMIZING NODAL SURGERY
Has replaced ALND as standard for nodal staging
![Page 21: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/21.jpg)
HISTORY OF AXILLARY STAGING
FOR BREAST CANCER
Formal axillary node dissection levels
2-3 standard of care for decades
NSABP B04 trial showed ALND not
associated with improved survival
With smaller tumors detected in
mammography screening, less node
positive
Thus nodes removed unnecessarily
![Page 22: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/22.jpg)
RATIONALE FOR LYMPHATIC MAPPING
AND SENTINEL NODE BIOPSY
Axillary dissection carries morbidity of lymphedema, decreased ROM and decreased sensation of upper inner arm
The status of the axillary nodes is the most important prognostic feature for breast cancer
If axilla accurately staged with a sentinel node biopsy which removes few nodes, then less morbidity of staging procedure
![Page 23: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/23.jpg)
SUMMARY OF SENTINEL NODE
BIOPSY SERIES DATA
False negative rate 0-12%
Success in identification of sentinel
node 70-100%, with most series better
than 90% success
Higher success in SLN identification
and lower false negative rates (<5%) in
series with more experience
![Page 24: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/24.jpg)
WHAT WE HAVE LEARNED
FROM CLINICAL TRIALS
ACOSOG Z0010- ? significance of IHC
occult mets
NSABP B32- ? Safety of SLND
compared to ALND
ACOSOG Z0011- role of ALND for
positive sentinel node
![Page 25: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/25.jpg)
ACOSOG Z10 TRIAL Giuliano, A. E. et al. JAMA 2011;306:385-393
To identify:
Prevalence and prognostic significance of sentinel lymph node (SLN) micrometastases and bone marrow (BM) micrometastases detected by immunohistochemistry (IHC)
• Assess risk of regional recurrence for SLN negative
by H&E
• Assess operative morbidity
Women with clinical T1-T2N0M0 breast cancer
![Page 26: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/26.jpg)
ACOSOG Z10 METHODS
5,539 patients (4/1999 - 5/2003)
Breast conserving surgery, Bone marrow aspiration and
sentinel node biopsy
Bone marrow specimens examined with IHC (investigators
blinded to results)
SLNs processed by standard pathology with H&E staining
SLNs negative by H&E examined with IHC for cytokeratin
(investigators blinded to results)
H&E node positive patients-
Axillary node dissection (ALND) or
Randomized on ACOSOG Z0011 study to no further
surgery or ALND
![Page 27: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/27.jpg)
Using a standard skill requirement surgeons
achieved a low SLN failure rate
98.7% SLN identification rate
Posther KE et al: Annals of Surgery 2005
Low complication rate for SLN dissection with
defined incidence of lymphedema
1-7% rate of various axillary complications
7% rate of lymphedema Wilke LG et al: Annals of Surg Oncology 2006
SURGICAL TECHNICAL OUTCOMES: Z0010
![Page 28: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/28.jpg)
ACOSOG Z10: FINDINGS
Sentinel Lymph node data
H&E: 24% positive for metastases
IHC: 10% of cases with micrometastases
Increasing breast tumor size is associated
with positive SLN
Bone marrow data – n= 3,413
ICC: 3% micrometastases
NO relationship to breast tumor size
![Page 29: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/29.jpg)
Bone Marrow Specimen Results and Cumulative Incidence of Death
Median follow-up 6.3 yrs
Giuliano, A. E. et al. JAMA 2011;306:385-393
Copyright restrictions may apply.
![Page 30: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/30.jpg)
Sentinel Lymph Node Results and Cumulative Incidence of Death
NO DIFFERENCE
Giuliano, A. E. et al. JAMA 2011;306:385-393
Copyright restrictions may apply.
![Page 31: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/31.jpg)
Conclusions from ACOSOG Z10
Outcome in this population was EXCELLENT- 5 year
overall survival of 93% in patients with H&E+ SLN
Occult SLN metastases detected by IHC not associated with
overall survival differences (95.7% IHC negative and 95.1%
for IHC positive)
Occult bone marrow metastases were significantly
associated with increased mortality
Routine IHC examination of H&E–negative SLNs and bone
marrow is not clinically warranted for early-stage (clinical
T1-T2N0) breast cancer.
Incidence BMA+ was too low to recommend incorporating
bone marrow aspiration biopsy into routine practice for
patients with clinical T1,2 N0M0 breast cancer
![Page 32: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/32.jpg)
NSABP B-32:
Largest prospective randomized phase III
trial of SLND alone vs SLND +ALND for
sentinel node negative
5,611 women with operable, clinically N0
Median follow-up 95 mos
![Page 33: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/33.jpg)
Kaplan-Meier Survival Estimates According to the Presence or Absence of Occult Metastases Detected in Initially Negative Sentinel Lymph Nodes.
Weaver DL et al. N Engl J Med 2011;364:412-421
![Page 34: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/34.jpg)
NSABP B32 Conclusions
• Significant difference overall survival between patients with IHC occult metastases and those in whom no occult metastases were detected (94.6% and 95.8%)
• Occult metastases were an independent prognostic variable in patients with sentinel nodes that were negative on initial examination; however, the magnitude of the difference in outcome at 5 years was small (1.2 percentage points)
• Data do not indicate a clinical benefit of additional evaluation with IHC for initially negative sentinel nodes in patients with breast cancer.
![Page 35: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/35.jpg)
COMPARISON ACOSOG Z10
AND NSABP B32
ACOSOG Z10 NSABP B32
Tumor size 1.4cm
T1 83% 80%
H&E pos SLNS 24% 26%
IHC pos SLNS 10.5% 15.9%
BMA positive 3% NA
Systemic Adjuvant 86% 78%
![Page 36: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/36.jpg)
MANAGEMENT OF THE POSITIVE
SENTINEL NODE
Standard of care :
Axillary Lymph Node Dissection
Is ALND necessary?
![Page 37: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/37.jpg)
RATIONALE TO AVOID ALND IN
SLN POSITIVE PATIENTS
SLN often the only positive node
Adjuvant therapy may treat
subclinical nodal metastases
Most data indicate that ALND
does not improve survival
ALND is for staging
![Page 38: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/38.jpg)
38
ACOSOG Z0011
A randomized trial of axillary node dissection
VS no axillary dissection in women with
clinical T1-2 N0 M0 breast cancer who have
a positive SN
Target accrual 1900 patients (non-inferiority)
• 4/1999 - 12/2004
• Closed early with 891 pts
![Page 39: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/39.jpg)
ACOSOG Z11 RESULTS:
REPORTED ASCO 6/2010
106 (27.4%) patients undergoing ALND had additional positive nodes removed beyond SN
Median follow-up = 6.3 years
Regional NODAL recurrence seen in only
0.7% of the entire population
![Page 40: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/40.jpg)
40
Locoregional Recurrence-Free Survival
![Page 41: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/41.jpg)
41
Summary
Locoregional recurrence in only 2.8% of
SLND and 4.1% of ALND patients
Only age (< 50) and higher Bloom-
Richardson score were associated with
locoregional recurrence by multivariable
analysis
Locoregional recurrence not related to
number of positive SNs, size of SN
metastasis, or number of lymph nodes
removed
Locoregional Recurrence-Free Survival
![Page 42: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/42.jpg)
42
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8
Time (Years)
% A
liv
e
ALND
No ALND
P-value = 0.25
Overall Survival
![Page 43: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/43.jpg)
43
Summary
No significant difference in DFS between
patients treated with SLND (83.9%) or ALND
(82.2%)
No significant difference in OS between
patients treated with SLND (92.5%) or ALND
(91.8%)
Only older age, ER-, and lack of adjuvant
systemic therapy - NOT OPERATION -
were associated with worse OS by
multivariable analysis.
Disease-Free and Overall Survival
![Page 44: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/44.jpg)
Z11 Conclusion
In this prospective randomized study - SLND
alone provided excellent
locoregional control and
survival comparable to
completion ALND for SLN node positive patients
![Page 45: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/45.jpg)
REMEMBER: APPLIES TO
SELECTED PATIENTS
• Initially clinically node negative
• Patients having breast conserving
surgery + radiation
• MASTECTOMY PATIENTS
EXCLUDED
• < 2 positive SLNs and no gross
extranodal extension
![Page 46: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/46.jpg)
ACOSOG Z10 AND Z11/ NSABP B32
PRACTICE CHANGING
• Abandon use of IHC to evaluate
sentinel nodes
• Abandon ALND for positive
sentinel node
![Page 47: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/47.jpg)
THANK YOU
![Page 48: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/48.jpg)
EVOLVING ROLE OF RADIATION IN
BREAST CANCER MANAGEMENT
After breast conserving surgery
Whole breast radiation
Accelerated partial breast radiation
After mastectomy
Positive margin
>3 positive nodes
Tumor > 5 cm with positive nodes
Stage III
Controversial: 1-3+ nodes
![Page 49: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/49.jpg)
Value of Local Control for Survival Lancet 366:2087, 2005
Oxford overview 2005
Node positive breast cancer
treated with mastectomy,
radiation reduced local recurrence
from 29% to 8% at 15 years
5% increase in overall survival for
node positive with radiation
![Page 50: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/50.jpg)
OVERCOMING RADIATION
CONCERNS: ACCELERATED
PARTIAL BREAST RADIATION Vicini, J Clin Oncol 2001;19:1993-2001,
Brachytherapy 1 (2002) 184–190
Administer radiation to lumpectomy site ONLY instead of whole breast
Treatment complete in 4-5 days instead of 5-7 weeks
Alternative methods of local radiation:
Internal devices
External beam
Limited to specific circumstances
Clinical trial at UT Southwestern for Cyberknife application of PBI
![Page 51: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/51.jpg)
INITIAL CRITERIA FOR SELECTING
PATIENTS FOR PARTIAL BREAST
RADIATION (PBI)
ABS ASBS
AGE >45 >50
HISTOLOGY
Node negative
Solitary tumor,
invasive ductal
Invasive or
in situ ductal
Tumor size < 3 cm < 2 cm
Margins Negative > 2 mm
![Page 52: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/52.jpg)
ACCELERATED PARTIAL BREAST IRRADIATION
CONSENSUS STATEMENT FROM
THE AMERICAN SOCIETY FOR RADIATION
ONCOLOGY (ASTRO) 2009
- Defined
Suitable candidates – age > 60
At variance with prior guidelines
Cautionary – age 50-59yrs
Unsuitable - < 50 yrs
![Page 53: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/53.jpg)
COMPARATIVE CRITERIA FOR
SELECTING PATIENTS FOR PARTIAL
BREAST RADIATION (PBI)
ABS ASBS ASTRO
AGE >45 >50 > 60
HISTOLOGY
Node negative
Solitary tumor,
invasive ductal
Invasive ductal
DCIS
Invasive ductal
no DCIS
Tumor size < 3 cm < 2 cm < 2cm
Margins Negative > 2 mm > 2 mm
![Page 54: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/54.jpg)
![Page 55: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/55.jpg)
![Page 56: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/56.jpg)
Breast Cancer Statistics, 2011 : Trends in Female Breast
Cancer Death Rates by Race and Ethnicity, 1975 to 2007
CA: A Cancer Journal for Clinicians
pages n/a-n/a, 3 OCT 2011 DOI: 10.3322/caac.20134
http://onlinelibrary.wiley.com/doi/10.3322/caac.20134/full#fig3
![Page 57: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/57.jpg)
Overall Survival by Bone Marrow IHC
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8 9 10
Time in Years
% A
live
Negative
Positive
P-value = 0.01
![Page 58: Local Regional Treatment: Examining Advances in Management of Breast Cancer, Dr. Marilyn Leitch - 7th Annual Breast Health Summit](https://reader034.vdocuments.net/reader034/viewer/2022051412/548747fbb47959e70c8b5424/html5/thumbnails/58.jpg)
58
Associations of Prognostic Variables
with Overall Survival
PR status
Tumor Size
Histologic Type
NS
0.042
0.020
Univariable Analysis
P value
Multivariable Analysis
P value
Adjuvant Systemic Therapy
NS Treatment Arm NS
0.044 # Positive Total LN NS
ER status 0.012 0.013
NS
Age (< 50, > 50) 0.002 0.006
0.025
NS
NS NS
LVI present vs. absent NS NS
Grade NS NS
NS SN Metastasis Size NS